Gary Sherman, DPM
Podiatrist · Brooklyn, NYNPI 1033135850
Payments from drug & device makers
Across 67 payments — averaging $52.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$1K
- Gotham Surgical Solutions & Devices, Inc.$1K
- Linvatec Corporation$298
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$87
- Kerecis Limited$72
- Zimmer Biomet$66
- plus $307 from 10 others
What the payments were for
- Speaking & faculty fees$63018%
- Food & beverage$1,67148%
- Education$1,20034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 39 | $1,472 |
| Gotham Surgical Solutions & Devices, Inc. | 1 | $1,200 |
| Linvatec Corporation | 1 | $298 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Kerecis Limited | 1 | $72 |
| Zimmer Biomet | 3 | $66 |
| Sebela Pharmaceuticals Inc. | 4 | $65 |
| Dynasplint Systems Inc. | 2 | $51 |
| Bioventus LLC | 2 | $34 |
| Merck | 2 | $33 |
| Amgen | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| GRT US Holding, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,501 in reported general payments places this provider in the 80th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 37 | $747 |
| Linezolid | 13 | $531 |
| Ketoconazole | 13 | $404 |
| Allopurinol | 12 | $152 |
| Silver Sulfadiazine | 16 | $152 |
| SsdSilver Sulfadiazine | 11 | $76 |
| Famotidine | 17 | $68 |
| Ibuprofen | 13 | $52 |
| Meloxicam | 17 | $20 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Brooklyn
- Scott GawlikBrooklyn$77K
- Rupinder BooraBrooklyn$10K
- Kevin JeongBrooklyn$10K
- Christopher BromleyPoughkeepsie$152K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.